A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT02311933

Title field or adapter rule

{'original_value': 'A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:30.330682+00:00

Published At

2021-09-28T00:00:00+00:00

Record Updated At

2026-10-26

Results Posted At

2021-09-28

Source Retrieved At

2026-10-31T22:18:24.976182+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Recurrent Breast Carcinoma", "Stage III Breast Cancer AJCC v7", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIC Breast Cancer AJCC v7", "Stage IV Breast Cancer AJCC v6 and v7"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-26", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT02311933"

protocolSection.identificationModule.officialTitle

"A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer"

protocolSection.statusModule.overallStatus

"ACTIVE_NOT_RECRUITING"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

{"date": "2021-09-28", "type": "ACTUAL"}

Study condition terms

• Recurrent Breast Carcinoma (protocolSection.conditionsModule.conditions)
• Stage III Breast Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
• Stage IIIA Breast Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
• Stage IIIB Breast Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
• Stage IIIC Breast Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
• Stage IV Breast Cancer AJCC v6 and v7 (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Arm I (z-endoxifen hydrochloride)'], 'description': 'Given PO', 'name': 'Endoxifen Hydrochloride', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Arm I (z-endoxifen hydrochloride)', 'Arm II (tamoxifen citrate)'], 'description': 'Correlative studies', 'name': 'Laboratory Biomarker Analysis', 'type': 'OTHER'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Arm I (z-endoxifen hydrochloride)', 'Arm II (tamoxifen citrate)'], 'description': 'Correlative studies', 'name': 'Pharmacological Study', 'type': 'OTHER'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Arm II (tamoxifen citrate)'], 'description': 'Given PO', 'name': 'Tamoxifen Citrate', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Endoxifen Hydrochloride (protocolSection.armsInterventionsModule.interventions[].name)
• Tamoxifen Citrate (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.